Completed NA INTERVENTIONAL 2-arm NCT02833298

Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening

Sponsor: Icahn School of Medicine at Mount Sinai

Conditions HCC HCV Hepatitis C Hepatocellular Carcinoma

Interventions Automated reminders Patient navigation

Updated 7 times since 2017 Last updated: Oct 10, 2018 Started: Nov 30, 2016 Primary completion: Apr 1, 2018 Completion: Apr 1, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02833298, this NA trial focuses on HCC and HCV and remains completed. Sponsored by Icahn School of Medicine at Mount Sinai, it has been updated 7 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Nov 2018 — Jan 2021 [monthly]

Completed NA

Status: Active Not Recruiting → Completed
Jun 2018 — Nov 2018 [monthly]

Active Not Recruiting NA

▶ Show 2 earlier versions

Nov 2017 — Jun 2018 [monthly]

Active Not Recruiting NA

Status: Recruiting → Active Not Recruiting · Phase: PHASE1 → NA
Jan 2017 — Nov 2017 [monthly]

Recruiting PHASE1

First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Icahn School of Medicine at Mount Sinai

Data source: Icahn School of Medicine at Mount Sinai

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States